e-Article
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or METamplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
Document Type
Article
Author
Wu, Yi-Long; Cheng, Ying; Zhou, Jianying; Lu, Shun; Zhang, Yiping; Zhao, Jun; Kim, Dong-Wan; Soo, Ross Andrew; Kim, Sang-We; Pan, Hongming; Chen, Yuh-Min; Chian, Chih-Feng; Liu, Xiaoqing; Tan, Daniel Shao Weng; Bruns, Rolf; Straub, Josef; Johne, Andreas; Scheele, Jürgen; Park, Keunchil; Yang, James Chih-Hsin; Wu, Yi-Long; Liu, Xiaoqing; Liu, Zhe; Lu, Shun; Chen, Xi; Pan, Hongming; Wang, Mengzhao; Yu, Shiying; Zhang, Helong; Zhang, Yiping; Fang, Jian; Li, Wei; Zhou, Jianying; Zhao, Jun; Cheng, Ying; Yang, Chih-Hsin; Chang, Gee-Chen; Chen, Yuh-Min; Hsia, Te-Chun; Chian, Chih-Feng; Yang, Cheng-Ta; Wang, Chin-Chou; Kim, Sang-We; Park, Keunchil; Kim, Dong-Wan; Cho, Byoung Chul; Lee, Ki Hyeong; Kim, Young-Chul; An, Ho Jung; Woo, In Sook; Cho, Jae Yong; Shin, Sang Won; Lee, Jong-Seok; Kim, Joo-Hang; Yoo, Seung Soo; Kato, Terufumi; Shinagawa, Naofumi; Soo, Ross Andrew; Tan, Shao Weng Daniel; Ngo, Lynette Si-Mien; Ratnavelu, Kananathan; Ahmad, Azura Rozila; Liam, Chong Kin; de Marinis, Filippo; Tassone, Pierfrancesco; Molla, Amelia Insa; Calles Blanco, Antonio; Lazaro Quintela, Martin Emilio; Felip Font, Enriqueta; Dingemans, Anne-Marie; Bui, Lynne
Source
The Lancet Respiratory Medicine; November 2020, Vol. 8 Issue: 11 p1132-1143, 12p
Subject
Language
ISSN
22132600; 22132619
Abstract
We evaluated the efficacy and safety of tepotinib, a potent and highly selective oral MET inhibitor, plus gefitinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with MET overexpression (immunohistochemistry [IHC]2+ or IHC3+) or METamplification having acquired resistance to EGFR inhibition.